Vertex Pharmaceuticals' Revenue Forecast Tops Expectations
1. Vertex anticipates 2025 revenue growth up to $12 billion. 2. Fourth-quarter revenue reached $2.91 billion, exceeding forecasts by analysts. 3. FDA's approval of Journavx marks a significant milestone in pain management. 4. Shares remain stable post-earnings, reflecting investor confidence. 5. Operating expenses surged, impacting adjusted earnings despite revenue growth.